Semaglutide Treatment for Hyperglycaemia After Renal Transplantation

PHASE4RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
HyperglycemiaRenal Transplant Complication Primary Non-FunctionDiabetes
Interventions
DRUG

Semaglutide 14 MG [Rybelsus]

At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.

DRUG

Placebo

Saline

Trial Locations (1)

2100

RECRUITING

Department og Nephrology and Endocrinology, Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

lead

Rigshospitalet, Denmark

OTHER